期刊
NEUROLOGICAL RESEARCH
卷 31, 期 9, 页码 931-939出版社
TAYLOR & FRANCIS LTD
DOI: 10.1179/174313209X395454
关键词
Contrast; enhancement; low-grade gliomas; malignancy; recurrence; survival
Objectives: Survival and tumor recurrence for patients with low-grade gliomas is heterogeneous, with reported survival and recurrence times varying by several months to years. The prognostic implications of a contrast-enhancing low-grade glioma remain less well understood. Methods: We retrospectively reviewed all adult patients who underwent a craniotomy for a hemispheric low-grade glioma (WHO grade II) from 1996 to 2006 at a single institution. Multivariate proportional hazards regression analysis was used to identify independent associations with survival, recurrence and malignant degeneration. Furthermore, a review of the literature for all works on low-grade gliomas and contrast enhancement was conducted. Results: One hundred eighty-nine patients (87 fibrillary astrocytomas, 89 oligodendrogliomas and 13 mixed gliomas) were available for analysis, with 64 (34%) and 125 (66%) contrast-enhancing and non-enhancing tumors, respectively. There were no significant differences in clinical and treatment-related variables between patients with and without contrast enhancement. After multivariate analysis, contrast enhancement was independently associated with decreased survival (p=0.006) and increased recurrence (p=0.04) and trended toward significance with malignant degeneration (p=0.15). Five-year overall survival, progression-free survival and malignancy-free survival rates for patients with enhancement versus patients without enhancement were 70 versus 85% (p=0.002), 32 versus 49% (p=0.008) and 74 versus 90% (p=0.002), respectively. The review of the literature identified 14 works that fit our criteria. The majority of these published works had design-related limitations including small population size as well as the inclusion of non-WHO grade II gliomas, pediatric patients and patient undergoing biopsy. Discussion: This study may provide insights into risk stratifying patients with low-grade gliomas and most specifically those that contrast enhance. [ Neurol Res 2009; 31: 931-939]
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据